Memantine Ratiopharm Gmbh

Memantine Hydrochloride, the active ingredient in Memantine Ratiopharm, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantine Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of dementia related to Alzheimer’s disease. - Moderate to severe Alzheimer’s disease: helps improve cognition, function and global clinical status in patients with established disease.

Adverse reactions may occur with memantine therapy and are reported as either common or serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Confusion: temporary mental clouding. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm. - Severe rash or Stevens‑Johnson syndrome: extensive skin involvement. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Suicidal ideation: thoughts of self‑harm. - Neuroleptic malignant‑like syndrome: high fever, muscle rigidity and autonomic instability.

Memantine should be used with caution in specific clinical situations and according to regulatory guidance. - Renal impairment: assess renal function and consider dose adjustment. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: use cautiously in patients with unstable heart conditions. - Concomitant NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy and breastfeeding: risk unknown; discuss potential benefits and risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring avoidance or close monitoring.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects. - Ketamine: combined CNS depression and potential for severe confusion. - Mefloquine: heightened risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish cognitive benefits of memantine. - Diuretics: possible alterations in blood pressure control. - CNS depressants (e.g., benzodiazepines): increased drowsiness and dizziness.